Cyclin-dependent kinase 4/6 inhibitors palbociclib or ribociclib combined with endocrine therapy and radiation therapy for patients with metastatic breast cancer

Background: The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) represented the standard I-II lines of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2 −) metastatic breast cancer (MBC). Data regarding toxicity safety profiles when combining CDK4/6i with palliative radiotherapy (RT) are still lacking. RT use with palliative and ablative intents is currently increasing due to promising results in the oligometastatic setting. We aim to investigate acute adverse events (AEs) before, at the start, two, and six weeks after RT completion.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS A: Advanced Disease Source Type: research